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Abstract: Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological
disease that mainly affects young adults. Our understanding of the pathophysiology of MS has
significantly advanced in the past quarter of a century. This has led to the development of many
disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients
with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt
the neurodegenerative changes associated with the disease. It is the purpose of this review to
provide concise information regarding mechanism of action, indications, side effects and safety
of Food and Drug Administration and European Medicines Agency approved agents for MS,
emerging therapies, and drugs that can be considered for off-label use in MS.
Keywords: disease-modifying therapies, emerging therapies, fingolimod, glatiramer acetate,
interferon β, multiple sclerosis, natalizumab

Introduction
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS) that mainly affects young
adults and may lead to significant disability over
time. Since the first documented case of MS in the
nineteenth century the knowledge regarding the
pathophysiology of the disease has significantly
advanced. The inflammatory cells in MS have
been well described and include CD4 and CD8
T lymphocytes, microglia and macrophages
[Goverman, 2011]. Also humoral immunity has
been described as an important component in
the pathophysiology of MS [Boster et al. 2010].
Within the past 30 years new and effective
therapies have been developed that decreased
clinical relapses, reduced new T2 and gadoliniumenhancing (Gad+) lesions and aim to halt the
progression of disease. Since the US Food and
Drug Administration (FDA) approval of the first
disease-modifying therapy (DMT) in 1993,
interferon (IFN)-β1b (Betaseron), which was
also approved in Europe in 1995 under the name
of Betaferon, we now have a total of eight FDAapproved therapies for MS, including an oral
agent and a single agent approved for secondary
progressive MS (SPMS) (Table 1). Of note, there
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are two agents approved by the European
Medicines Agency (EMA) for the treatment of
SPMS, mitoxantrone and IFN-β1b (Betaferon/
Extavia). All first-line injectable agents have
been studied in clinically isolated syndrome
(CIS) and have demonstrated decreased risk of
conversion into clinically definite MS (CDMS)
(Table 2) [Kappos et al. 2006; Jacobs et al. 2000;
Comi et al. 2001, 2009, 2012a]. So far there is
no effective therapy to halt progression of disease
and reduce disability in primary progressive MS
(PPMS).
There are many new agents in the pipeline which
will bring great choices into the MS pharmacological armamentarium (Table 3).
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FDA- and EMA-approved therapies
Interferon β
IFNs are a family of proteins that play a role in
the body’s natural defense against microbial, neoplastic and viral insults and have a role in regulating the immune response. IFN-β impacts the
immune system in several ways, such as decreasing major histocompatibility complex (MHC)
class II expression, upregulation of interleukin 10
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Table 1. Current Food and Drug Administration/European Medicines Agency approved therapies for multiple
sclerosis (MS)
Disease-modifying
therapy

Dose/route

Monitoring labs/tests

Side effects*

IFN-β1a (Avonex)

30 μg intramuscularly
weekly

CBC, LFTs, TSH

IFN-β1a (Rebif)

22 or 44 μg
subcutaneously three
times a week

CBC, LFTs, TSH

IFN-β1b
(Betaseron/
Betaferon/Extavia)

250 μg subcutaneously
every other day

CBC, LFTs, TSH

Glatiramer acetate
(Copaxone)

20 mg subcutaneously
once a day

None

Mitoxantrone

12 mg/m2 intravenously
over 30 min every
3 months with a lifetime
cumulative dose of no
more than 140 mg/m2;
frequency may vary
300 mg intravenously
every 28 days

CBC, LFTs, U/A, LVEF

0.5 mg orally once a
day

CBC, LFTs, screen
for macular edema

Flu-like symptoms,
depression, thyroid
dysfunction, liver enzymes
abnormalities
Skin site reactions, flu-like
symptoms, depression,
thyroid dysfunction, liver
enzymes abnormalities
Skin site reactions, flu-like
symptoms, depression,
thyroid dysfunction, liver
enzymes abnormalities
Skin site reactions,
immediate postinjection
reaction, lipoatrophy
Hair loss, cardiotoxicity,
leukemia, infertility,
increased risk of
infections, leukopenia,
anemia, nausea, vomiting,
thrombocytopenia
Transient headache fatigue,
recurrent UTIs, PML,
hypersensitivity reaction
First-degree AV block with
first dose, bradycardia,
macular edema, shingles,
PF dysfunction in selected
patients, skin cancer, back
pain

Natalizumab
(Tysabri)
Fingolimod

CBC, LFTs

AV, atrioventricular; CBC, complete blood count; IFN, interferon; LFT, liver function test; LVEF, left ventricular ejection
fraction; PML, progressive multifocal leukoencephalopathy; PF, pulmonary function; TSH, thyroid-stimulating hormone;
U/A, urinalysis; UTI, urinary tract infections.
*Selection of side effects, not full side effects profile.

(IL-10) production, and decreased T helper (Th)-1
and Th17 production, which leads to an overall
anti-inflammatory effect [Kieseier, 2011; Kappos
et al. 2007].
Subcutaneous interferon β1b (Betaseron, Bayer
Schering Pharma AG/Betaferon, Bayer Schering
Pharma AG/Extavia, Novartis Pharmaceuticals
Corp.). The pivotal phase III trial using IFN-β1b
was a randomized, double-blind, placebo-controlled, multicenter trial of 372 patients with
RRMS over 2 years. This trial demonstrated a
34% reduction in overall relapses compared with
placebo. More specifically, there was a 50% reduction in annualized relapses classified as moderate
to severe in the treatment group. Patients receiving IFN-β1b were also found to have a lower T2
206

lesion volume and decreased accumulation of new
lesions [IFNB Multiple Sclerosis Study Group.
1993]. Each of the IFN-β therapies, as well as
glatiramer acetate, has been shown to delay conversion to CDMS in patients with CIS (Table 2).
In the 5-year active treatment extension of the
BENEFIT trial, the effects of early versus delayed
treatment with IFN β1b were investigated. This
study showed the risk of conversion to CDMS
remained lower in the group receiving early treatment; 46% compared with 57% of patients converting from CIS to CDMS [hazard ratio (HR)
0.63; 95% confidence interval (CI) 0.48–0.83; log
rank test p = 0.003) [Kappos et al.2009].
Intramuscular interferon β1a (Avonex, Biogen Idec,
Inc.). In the pivotal trial including 301 patients
http://tan.sagepub.com
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Table 2. Pivotal trials for approval of disease-modifying therapies in clinically isolated syndrome
Trial

Drug

Result

Reference

BENEFIT

IFN-β1b

Kappos et al. [2006]

CHAMPS

IFN-β1a
intramuscularly

ETOMS

IFN-β1a
subcutaneously

REFLEX

IFN-β1a
subcutaneously

PreCISe

Glatiramer acetate

Conversion risk at 2 years 28%
with interferon β-1b versus
45% with placebo
Conversion risk at 2 years
was 35% with interferon β-1a
intramuscularly versus 50%
with placebo
Conversion risk at 2 years
was 34% with interferon β-1a
subcutaneously versus 45%
with placebo
Conversion risk at 2 years
was 20.6% for three times per
week dose, and 21.6% for once
a week dose versus placebo
Conversion risk at 2 years was
25% with glatiramer acetate
versus 43% with placebo

Jacobs et al. [2000]

Comi et al. [2001]

Comi et al. [2012]

Comi et al. [2009]

BENEFIT, Betaseron/Betaferon in newly emerging multiple sclerosis for initial treatment; CHAMPS, the controlled high
risk Avonex multiple sclerosis trial; ETOMS, early treatment of multiple sclerosis; IFN, interferon; PreCISe, effect of
glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome;
REFLEX, REbif FLEXible dosing in early MS.

with RRMS, IFN-β1a intramuscularly was shown
to delay time to progression of disability with
fewer treated subjects experiencing disability progression (21.9% versus 34.9%; p = 0.02) compared with placebo. Annualized relapse rates
(ARRs) over a 2-year period were also lower compared with placebo (ARR 0.61 versus 0.90; p =
0.03). The accumulation of Gad+ lesions was also
reduced; however, T2 lesion volume was not significantly different between the two groups at 2
years [Jacobs et al. 1996].
Subcutaneous interferon β1a (Rebif, EMD Serono,
Inc.). The Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) trial was a 2-year
randomized, double-blind, placebo-controlled,
multi-centered trial of 560 patients with RRMS.
Subjects treated with either the 22 or 44 μg dose
of IFN-β1a subcutaneously showed a significant
reduction in ARRs compared with placebo, 27%
and 33% respectively. Both treatment groups
showed a significant reduction in the number of
new or enlarging T2 lesions; 67% reduction in
the 22 μg group and 78% reduction in the 44 μg
group [PRISMS Study Group, 1998]. An extension study utilizing a crossover design in which
placebo-treated patients were randomized to
either 22 or 44 μg of IFN-β1a subcutaneously
after 2 years revealed patients in both active
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treatment groups for the entire 4 years continued to show significantly lower number of relapses
per year [PRISMS Study Group, 2001]. IFNs
have immunogenic properties and treated individuals may develop binding and neutralizing
antibodies (NAbs) to these products. NAbs may
develop with the use of all formulations of IFNβ; however, they are found more commonly with
the high-dose, high-frequency IFNs (IFN-β1b
and IFN-β1a subcutaneously). The issue of
NAbs is controversial; however, a panel of
experts met at the Neutralizing Antibodies on
Interferon Beta in Multiple Sclerosis (NABINMS) consortium in 2009 in attempts to formulate a practical approach to the evaluation
and incorporation of information regarding
NAbs in the treatment of MS. The group proposed that both the NAb titer and clinical status
of the patient should be considered in the decision regarding the impact of the presence of
NAbs on changing DMTs. They also suggested
reevaluation of the NAbs status prior to making
a change in therapy unless patients were clearly
performing poorly clinically [Polman et al. 2010].
Glatiramer acetate
Glatiramer acetate (GA) (Copaxone, Teva Neuro
science North America / Teva Pharmaceuticals)
is a first-line therapy for relapsing forms of MS
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Table 3. Multiple sclerosis emerging therapies.
Current agents
in the pipeline

Mechanism of
action

Phase

Administration

Results

Adverse effects

Laquinimod

May modulate
Th1 to Th2
cytokine shift

III

Oral
0.6 mg daily

LFT elevation

Teriflunomide

Inhibits DNA
pyrimidine
synthesis in dividing
cells such as T and
B cells

III

Oral
7 and 14 mg
daily

Dimethyl
fumarate
(BG-12)

Modulates
oxidative pathways
and decreases
autoimmunity

III

Oral
120–240 mg
three times a
day

Alemtuzumab

Antibody binds
CD52 to cause
destruction of
circulating immune
cells

III

Daclizumab

Block the IL-2
receptor/
anti-CD25

II

Intravenous
infusion
12 or 24 mg daily
for 5 days on
month 0 and 12
or 24 mg daily
for 3 days on
month 12
Subcutaneous
2 mg/kg every 2
weeks

23% reduction in
relapse rate; 37%
reduction in contrast
enhancing lesions
61% reduction in
contrast enhancing
lesions, reduces
ARR by 30%,
reduces disability
progression by
23–30%
69% reduction in
contrast enhancing
lesions (phase II
trial); DEFINE phase
III trial showed
53% reduction in
ARR; 38% reduction
in disability
progression, and
reduced disability
progression in
2 years by 49%
Up to 75% reduction
in sustained
accumulation
disability; up to 74%
reduction in relapse
rate

Ocrelizumab

Antibody targets
CD20 and mediates
destruction of
B cells

II

72% reduction in
contrast enhancing
lesions, decreased
disease progression
by up to 57% in
1 year, decreased
ARR by 50–54%
Reduced brain
lesions by 89% and
96%, reduced ARR
by 80% and 73%

Infusion reaction,
serious skin rash,
lymphadenopathies,
LFT abnormalities,
liver toxicity,
diarrhea,
constipation
Systemic
inflammatory
response (one lethal
case), infusion site
reactions

600 mg,
2000 mg
intravenous
infusions

Nasopharyngitis,
headache, diarrhea,
fatigue, back
pain, influenza,
hair thinning, LFT
elevation, nausea,
UTI
Diarrhea, cramps,
LFT elevation, nausea
and flushing

Immune
thrombocytopenic
purpura, autoimmune
thyroid-related
problems, headaches,
flushing

ARR, annualized relapse rate; DEFINE, efficacy and safety of oral BG00012 in relapsing remitting multiple sclerosis; HZV, Herpes Zoster
virus; LFT, liver function test; Th, T helper; UTI, urinary tract infection.

and CIS. GA contains an incalculable number
of active amino acid sequences and is composed
of a large number of synthetic peptides. The
usual dose of GA is 20 mg subcutaneously once
a day.
The mechanism of action (MOA) of GA is not
completely understood, but consists of an antigenpresenting cell (APC) incorporating peptides of
208

GA and presenting them to a lymphocyte, similar
to the process of a vaccine. This process creates a
unique population of lymphocytes circulating in
the blood which are responsive to GA. It inhibits
the multiplication of human lymphocytes that
are capable of reacting to myelin basic protein.
Researchers have been able to show that GA
binds directly to the portion of the APC that is
required to stimulate the T lymphocyte, thus
http://tan.sagepub.com
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blocking direct immunologic attack. It was in the
late 1980s that the immunologic concept of Th1
(proinflammatory) and Th2 (anti-inflammatory)
lymphocytes gained momentum. These two types
of lymphocytes can be identified by the chemicals
that they manufacture and then secrete. These
chemicals are known as cytokines, and can be
divided into inflammatory and proinflammatory.
In 1997, Aharoni and colleagues published a
paper that described how GA could stimulate the
production of Th2 (anti-inflammatory) cells that
inhibited the inflammatory response by secreting anti-inflammatory cytokines [Aharoni et al.
1997]. The GAs’ effect begins in the peripheral
tissues in a population of specific lymphocytes
which circulate in the blood and are capable of
migrating into the CNS tissue by crossing the
blood–brain barrier (BBB). These cells then
encounter fragments of several myelin proteins
that stimulate the glatiramer cells to multiply and
begin to produce anti-inflammatory cytokines.
Since the glatiramer-activated lymphocytes can
suppress inflammation under way in the diseased
area of CNS tissue, this process has been given
the name bystander suppression [Johnson, 2010].
To date, data suggest that GA treatment is associated with a broader immunomodulatory effect on
cells of not only the innate but also the adaptive
immune system. Recent investigations indicate
that GA treatment may also promote regulatory
B-cell properties [Lalive et al. 2011].
GA has a relatively narrow adverse effect profile.
Most frequently patients complain of mild pain
and pruritis at the injection site. Lipoatrophy and
skin site reactions are also seen and may lead to
discontinuation of therapy. A transient reaction
called immediate postinjection reaction consists
of chest tightness, flushing and dyspnea beginning soon after the injection and lasting no longer
than 20 min. If no history or evidence of coronary
artery disease, the patient can be reassured that
such a reaction is benign [DiPiro et al. 2005].
Multicenter trials with GA have demonstrated
statistically significant reductions in mean ARR
that are comparable to those of the IFNs [DiPiro
et al. 2005]. In two recent studies the efficacy of
GA was compared with high-dose/high-frequency
IFN-β. In the Rebif versus Glatiramer Acetate in
Relapsing MS Disease (REGARD) study [Mikol
et al. 2008], subcutaneous IFN-β1a was compared
with GA, and in the Betaseron/Betaferon Efficacy
Yielding Outcomes of a New Dose (BEYOND)
study [O’Connor et al. 2009], subcutaneous
http://tan.sagepub.com

IFN-β1b was compared with GA. In both trials,
there was no significant difference between IFN
and GA in the primary endpoints or in any clinical endpoints, although some differences in magnetic resonance imaging (MRI) measures of
disease activity have been claimed.
The results from a 15-year analysis of the US
prospective open-label study of GA indicate that
long-term continuous use is safe. It also indicates
that the majority of patients continuing on GA
therapy in the study have had few relapses and
minimal disease progression. Of the initial 232
patients that received at least one GA dose since
study initiation in 1991, only 100 (43%, ongoing
cohort) patients continued. Of the 100 patients
receiving continuous GA as sole immunomodulatory therapy for 15 years (mean disease duration
of 22 years and mean patient age of 50 years) have
not transitioned to SPMS, 57% have retained stable or improved the Expanded Disability Status
Scale (EDSS) scores over the course of the study
and 82% remain ambulatory without mobility aids.
There was no occurrence of any unforeseen adverse
events in patients receiving GA therapy. The study
will continue for 20 years of prospective follow up
[Ford et al. 2010].
Mitoxantrone
Mitoxantrone is an anthracenedione initially
developed as an anti-neoplastic agent that reduces
lymphocyte proliferation. Mitoxantrone intercalates into DNA strands, inducing strand breakage
and inhibition of the DNA repair enzyme topoisomerase II. It is an immunosuppressive agent
used as a second-line treatment for SPMS, primary relapsing multiple sclerosis and worsening
RRMS. Mitoxantrone was approved for the treatment of SPMS based on the study by Hartung
and colleagues [Hartung et al. 2002].
Several studies have shown it to be efficacious in
reducing exacerbations and number of Gad+
lesions on MRI, and it seems to have effects on
disease course up to 5 years after discontinuing
therapy [Martinelli et al. 2009; Goodin et al. 2003].
Mitoxantrone is given as an intravenous infusion
over 30 min every 3 months at 12 mg/m2 for a 2to 3-year period with a maximum cumulative dose
of 140 mg/m2. Common side effects include alopecia, nausea and vomiting, an increased risk of
infection (particularly urinary and respiratory
tracts infections) and amenorrhea. Mitoxantrone,
though effective, remains second line due to its
209
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risk of two serious adverse effects that can occur
at any time after the first dose is given. The first,
acute leukemia has an incidence of approximately
0.81% [Marriott et al. 2010]. Regular monitoring of complete blood counts is recommended.
Mitoxantrone can also cause decreased left ventricular ejection fraction (LVEF) and congestive
heart failure at a rate of approximately 12% and
0.4%, respectively [Marriott et al. 2010]. To
monitor cardiotoxicity, a baseline LVEF must be
obtained and any patient with an ejection fraction
less than 50% should not receive mitoxantrone.
It was previously believed that cardiotoxicity could
only occur with cumulative doses over 96–140
mg/m2; however, several reports of cardiotoxicity
below this threshold have caused the FDA to recommend monitoring cardiac function before every
infusion. The therapy must be discontinued if the
LVEF ever falls below 50% or decreases by 10%
[Martinelli et al. 2009].
Natalizumab
Migration of leukocytes from the vasculature
into the parenchyma involves the interaction
between leukocyte adhesion molecules and their
complementary ligands on vascular endothelial
cells. Leukocyte integrins are heterodimeric glycoproteins that contain an α and β chain
[Ransohoff, 2007]. Vascular cell adhesion molecule 1 (VCAM-1) is expressed on the surface of
vascular endothelial cells in the blood vessels
within the CNS and interacts with α4β1 integrin
on lymphocytes to allow for extravasation across
the BBB. Also, the interaction of α4β1 integrin
with fibronectin and osteopontin may modulate
the survival, priming and activation of leukocytes
that have entered into the parenchyma of the
brain and spinal cord. Natalizumab (Tysabri,
Biogen Idec, Inc.) contains humanized immunoglobulin G4κ monoclonal antibodies against leukocyte α4 integrins, including α4β1 and α4β7
integrins, and blocks binding to their endothelial
receptors (VCAM-1 and mucosal addressin cell
adhesion molecule 1, respectively) [Polman et al.
2006]. By blocking α4 integrins, natalizumab
inhibits the migration of leukocytes into the
brain, which results in reduced inflammation.
Natalizumab was evaluated for the treatment
of RRMS in two phase III clinical trials. The
Natalizumab Safety and Efficacy in relapsing
remitting multiple sclerosis (AFFIRM) study
evaluated 942 patients who were randomly
assigned to receive natalizumab versus placebo
210

every 4 weeks for 2 years. The primary endpoints
were the rate of clinical relapse at 1 year and
the rate of sustained progression of disability,
measured by the EDSS, at 2 years. Natalizumab
reduced the risk of sustained disability by 42%
over 2 years (HR 0.58; 95% CI 0.43–0.77; p <
0.001). It reduced the rate of clinical relapse at
1 year by 68% (p < 0.001). MRI scans were
obtained at baseline, 1 year and 2 years.Treatment
with natalizumab resulted in an 83% reduction of
new or enlarging hyperintense T2 lesions over 2
years (mean number of lesions 1.9 with natalizumab and 11 with placebo; p < 0.001). There
were 92% fewer Gad+ lesions in the natalizumab
group than in the placebo group at 1 and 2 years
(p < 0.001). There was also a significant effect on
Gad+ lesions seen after 6 weeks of natalizumab
treatment [Polman et al. 2006].
The Safety and Efficacy of Natalizumab in combination with IFN-β1a in patients with RRMS
(SENTINEL) trial was a 2-year phase III trial
evaluating treatment with natalizumab or placebo
in combination with IFN-β1a. The primary endpoints were the rate of clinical relapse at 1 year
and accumulative probability of disability progression, measured by the EDSS, at 2 years. The
study showed that treatment with both drugs was
more effective than treatment with IFN-β1a
alone. Patients on combination treatment were
less likely to have sustained disability progression
(23% versus 29%) and were more likely to remain
relapse free (61% versus 37%). Combination
treatment resulted in fewer new or enlarging T2
lesions (0.9 versus 5.4; p < 0.001) [Rudick et al.
2006]. The study ended a month early due to the
occurrence of progressive multifocal leukoencephalopathy (PML) in two patients who received
natalizumab with IFN-β1a.
The most notable potential adverse effect of natalizumab treatment is the development of PML.
Following the observation that three patients
treated with natalizumab developed PML, it was
withdrawn from the market in February 2005
and reintroduced in July 2006 as monotherapy
treatment for RRMS. The original risk of PML
was estimated to be approximately one per 1000
patients receiving natalizumab [Berger, 2010]. As
of 4 January 2012, approximately 96,582 patients
have received natalizumab since it was marketed
and there have been 201 confirmed cases of PML
worldwide. Approximately 20% of patients who
have developed PML have died. Those that survived have varying levels of disability, ranging
http://tan.sagepub.com
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from mild to severe. Fewer patients treated and
wide confidence intervals result in questionable
estimates beyond 30 months of treatment.
PML is a rare demyelinating disease of the
brain due to the John Cunningham (JC) virus. It
is almost always seen in association with an
underlying immunosuppressive condition. The
precise explanation for the increased risk of PML
with natalizumab therapy remains unknown.
In the natalizumab clinical trials, there was a
small increase in the rate of infections, including
herpes infections, pneumonia and urinary tract
infections. There were no other opportunistic
infections or increase cases of cancer reported
[Ransohoff, 2007]. Post-release monitoring disclosed one case of fatal herpes encephalitis,
one nonfatal case of herpes meningitis, cryptosporidium gastroenteritis, pneumocystis carinii
pneumonia, varicella pneumonia and mycobacterium avium intracellular complex pneumonia
[Ransohoff, 2007; Gorelik et al. 2010].
Natalizumab infusions were complicated by serious hypersensitivity reactions, including fever,
rash and anaphylaxis, in less than 1% of patients
and less serious infusion reactions in about 4% of
patients [Ransohoff, 2007; Polman et al. 2006;
Rudick et al. 2006]. Patients with infusion reactions were more likely to have persistent NAbs.
The presence of antibodies lessoned natalizumab’s clinical efficacy and resulted in clinical and
radiographic disease activity equivalent to patients
in the placebo group [Ransohoff, 2007].
Natalizumab is an extremely effective therapy
for RRMS and is licensed for highly active naïve
patients. Due to the potential risk of PML and
other opportunistic infections, it is typically
reserved for patients with clinically or radiographically extremely active disease either as
initial therapy or when initial therapy has been
ineffective or poorly tolerated. Treatment with
natalizumab requires rigorous ongoing clinical
surveillance. To minimize the risk of PML,
patients beginning treatment should have no
history of immunosuppressive medications in
the preceding 3 months and should not have
other conditions that may compromise cellmediated immunity. The FDA and EMA recommend the use of the JC virus antibody for
risk stratification on all patients on Tysabri. The
risk of PML increases after 24 months on therapy, if there has been prior immunosuppressant
http://tan.sagepub.com

use and the presence of JC virus antibody.
Patients with positive JC virus antibody, prior
treatment with an immunosuppressant and who
have received more than 24 doses of Tysabri
have an estimated risk of PML of 9–11/1000.
However, patients without any of those risk factors for PML have a risk of PML of less than
0.1 per 1000 [Sorensen et al. 2012].
Fingolimod
Fingolimod is an oral sphingosine-1 phosphate
(S1P) receptor modulator. It was approved by the
FDA in September 2010 as first-line therapy for
RRMS. However, the EMA has recommended
that its use be limited to those whose condition
fails to respond to first-line therapy or only in
cases of severe, rapidly developing cases of MS. It
acts as a sphingosine analogue, binding to the
S1P1 receptor on lymphocytes leading to internalization and downregulation of their expression
and thereby preventing the egression of lymphocytes from the lymph nodes. Additionally, through
interactions with S1P receptors on neural cells,
fingolimod has been shown to have potentially
neuroprotective effects in the animal experimental autoimmune encephalomyelitis model [Foster
et al. 2007; Coelho et al. 2007; Miron et al. 2008].
In the 24-month phase III FTY720 Research
Evaluating Effects of Daily Oral therapy in
Multiple Sclerosis (FREEDOMS) trial comparing placebo with oral fingolimod at doses of 1.25
mg and the now FDA-approved 0.5 mg daily
dose, there was a significant reduction in ARR
with both doses of fingolimod (0.16 at 1.25 mg
and 0.18 at 0.5 mg) compared with placebo
(0.40) which represented a relative reduction of
60% and 54%, respectively. Furthermore, fingolimod also reduced the risk of disability progression with a probability of disability progression
(confirmed after 3 months) of 17.7% at the 0.5
mg dose and 16.6% at the 1.25 mg dose compared with 24.1% with placebo. Almost 90% of
patients receiving fingolimod, at either dose, were
free of enhancing lesions over the course of 2
years and approximately 50% were free of new or
enlarging T2 lesions [Kappos et al. 2010].
The Trial Assessing Injectable Interferon versus
FTY720 Oral in RRMS (TRANSFORMS) comparing fingolimod with intramuscular INF-β1a
showed a 52% relative reduction in ARR in the
patients treated with fingolimod 0.5 mg versus
IFN. This study showed a similar beneficial
211
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effect on MRI markers compared with IFN-β1a;
however, there was no statistically significant
difference in the disability progression between
the fingolimod and IFN-β1a groups [Cohen et al.
2010].
Despite its efficacy, there are additional safety
concerns compared with the injectable therapies.
Data from the two pivotal trials showed an
increased risk of infections, cardiovascular effects,
including bradycardia and atrioventricular (AV)
block (first and second degree) with initial dosing
and macular edema. Each of these was more
common with the higher 1.25 mg dose. Of note,
there were two deaths related to infections in subjects receiving fingolimod at the 1.25 mg dose in
TRANSFORMS. One death was secondary to a
dissemination varicella zoster infection and the
second was related to herpes simplex encephalitis.
While herpes virus infection has been seen at
the 0.5 mg dose, cases tended to be mild and
were not found to occur at a higher rate than the
control arm [Cohen et al. 2010].
The EMA recently recommended increased
patient monitoring during the first dose of fingolimod, including electrocardiogram monitoring before treatment and then continuously for
the first 6 h after the first dose is administered,
and measurement of blood pressure and heart
rate every hour over the same 6 h.
Off-label therapies
Immunosuppressive agents, chemotherapies and
various mAbs have been used off label for many
years as DMTs in MS but the potential benefits
of these therapies are limited by systemic adverse
events, such as increased risk of malignancy and
opportunistic infections. These agents have been
used in patients who are refractory to or cannot
tolerate the side effects of IFN-β and GA, cannot
afford FDA-approved therapies, or need intensification of therapy (i.e. used in combination with
IFN-β or GA). Also limiting the use of these medications is the lack of large-scale, controlled trials,
validating their efficacy.
Mycophenolate mofetil
Mycophenolate mofetil (MMF; Cellcept, Roche
Laboratories, Nutley, NJ, USA) is FDA and EMA
approved for preventing rejection of cardiac, liver
and renal transplants. MMF undergoes rapid and
complete metabolism to mycophenolic acid (MA),
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which is the active metabolite. MA is a potent,
selective, noncompetitive and reversible inhibitor
of inosine 5’ monophosphate dehydrogenase type
II. MA inhibits the de novo synthesis pathway of
guanosine nucleotides without being incorporated
into DNA. Because T and B lymphocytes are
critically dependent for their proliferation on de
novo synthesis of purines, while other cell types
can utilize salvage pathways, MA has potent cytostatic effects on lymphocytes. MA inhibits proliferative responses of T and B lymphocytes to both
mitogenic and allospecific stimulation. MA also
suppresses antibody formation by B lymphocytes
[Product information: Cellcept, 2009].
Potential side effects include hypertension, backache, abdominal pain, diarrhea, nausea, elevated
transaminases, vomiting, anxiety and tremor.
Serious side effects include gastrointestinal bleeding, thrombocytopenia, skin cancer, opportunistic
infection and PML. Increased susceptibility to
infection and the possible development of lymphoma may result from immunosuppression.
A retrospective review of experience in treating
79 patients with MS with MMF showed that
this agent was well tolerated by the majority of
patients. Patients were initiated on 500 mg twice
a day, which was titrated up by 500 mg weekly
to a maximum of 1000 mg twice a day. While the
observations were uncontrolled, some of the
patients demonstrated either stabilization or
improvements in their activities of daily living,
ambulation and relapse rate [Frohman et al.
2004]. In a randomized, MRI-blinded, parallel
group, pilot trial of MMF compared with IFNβ1a, both drugs appeared safe and well tolerated in the majority of patients. The trial also
showed a trend toward a lower accumulation of
combined active MRI lesions. MMF showed a
nonstatistically significant increase in infections
[Frohman et al. 2010]. The dose generally used
in patients with RRMS is 1000 mg twice daily.
Large, randomized clinical trials are needed to
better evaluate the safety and efficacy of this
agent in patients with MS.
Azathioprine
Azathioprine is FDA approved for rejection prophylaxis (as monotherapy or adjunct) of renal transplant and rheumatoid arthritis (RA). Although
not FDA approved, it has been used in the USA
to treat MS since 1971 [La Mantia et al. 2007].
Azathioprine is licensed for MS therapy in
http://tan.sagepub.com
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Germany. Azathioprine is an imidazole derivative
of 6-mercaptopurine and acts as an immunosuppressive antimetabolite. It is a purine antagonist
and affects DNA replication. It impairs T-cell
lymphocyte function and is more selective for
T lymphocytes than for B lymphocytes [Casetta
et al. 2009]. The Cochrane MS Group concluded
that azathioprine is an appropriate maintenance
treatment for patients with MS and could be a fair
alternative to IFN. It is recommended that cumulative doses do not exceed 600 g due to possibly
increasing the risk of malignancies [Casetta et al.
2009].
Methotrexate
Methotrexate (MTX) is a chemotherapeutic agent
used for the treatment of severe psoriasis, juvenile
RA (JRA), severe RA, acute lymphoid leukemia
and other malignancies. MTX reversibly inhibits
dihydrofolate reductase. Via this mechanism, MTX
sodium interferes with DNA synthesis, repair
and cellular replication [Product information:
methotrexate, 2000, 2005].
On a systematic review of oral MTX for MS, for
the Cochrane Multiple Sclerosis Group, the
authors do not recommend the use of MTX for
progressive MS or RRMS due to a lack of highquality evidence. Future trials need to be performed
using standard outcome measures and objective
measures, such as MRI [Gray et al. 2004].
Rituximab
Rituximab is FDA approved for the treatment of
non-Hodgkin’s lymphoma, chronic lymphocytic
leukemia, refractory moderate to severe RA,
Wegener’s granulomatosis and microscopic polyangiitis [Prescribing information, 2010]. It is
EMA approved for diffuse large B-cell lymphoma and autoimmune arthritis. Rituximab is
a chimeric murine/human mAb that targets and
selectively binds CD20, an antigen present on
pre-B cells and B cells, but not on antibodyproducing plasma cells or stem cells in the bone
marrow. By binding CD20, rituximab depletes
circulating B-cell populations (but not stem cells
or plasma cells) through a combination of cellmediated and complement-dependent cytotoxicity and possibly promoting apoptosis [Bar-Or
et al. 2008].
Common side effects of rituximab include nasopharyngits, urinary tract infections, nausea,
http://tan.sagepub.com

leucopenia, fever, fatigue, headache, muscle
spasms and diarrhea. Cases of PML, severe
mucocutaneous reactions, tumor lysis syndrome
and fatal infusion reactions have been documented. Other severe adverse reactions include
fulminant hepatitis, hepatic failure, bacterial,
fungal or viral infections, cardiac arrhythmias,
renal toxicity and bowel obstruction or perforation [Prescribing information, 2010].
In a 72-week, open-label phase I trial the safety
and tolerability of rituximab were evaluated in 26
patients with RRMS. The authors indicated that
no serious adverse events were reported in this
small cohort with active RRMS and all the
adverse events including infections were mild to
moderate and did not lead to medication withdrawal. No efficacy conclusions were noted due
to the absence of a control group but they noticed
a reduction in relapses, Gad+ lesions, new T2
lesion number and T2 lesion volumes through
72 weeks [Bar-Or et al. 2008]. In a phase II
randomized, placebo-controlled trial with 104
patients there was a reduction in Gad+ lesions
and relapses in patients on rituximab versus placebo [Hauser et al. 2008]. Rituximab has shown
efficacy in the treatment of patients with RRMS.
A recently completed randomized clinical trial
using a standard dose of rituximab in patients with
RRMS demonstrated a 91% reduction in the
number of Gad+ lesions on MRI, as well as a significant reduction in the number of clinical
relapses [Hauser et al. 2008]. In a recent trial of
patients with PPMS, rituximab appeared to have
efficacy only in young patients (primarily male)
with signs of active inflammation on MRI scans
[Hawker et al. 2009]. Manufacturers of rituximab
decided not to go forward with phase III trials,
but other CD20 molecule manufacturers are
undertaking phase III trials.
Immunoglobulin
While several studies have suggested a beneficial
effect of intravenous immunoglobulin (IVIG) in
RRMS [Fazekas et al. 1997; Achiron et al. 1998;
Lewanska et al. 2002] and CIS [Achiron et al.
2004] in terms of relapse rate, MRI and disability progression, there were limitations in terms
of methodology and sample size. The most
recent published trial from the Prevention of
Relapse with Intravenous Immunoglobulin
(PRIVIG) study group brought the efficacy of
IVIG as a preventative agent in MS into question [Fazekas et al. 2008]. Current guidelines
213

Therapeutic Advances in Neurological Disorders 5 (4)
from the European Federation of Neurological
Societies recommend that IVIG be considered
as a second- or third-line therapy in RRMS if
conventional immunomodulatory therapies are
not tolerated [Elovaara et al. 2008]. However,
IVIG is widely used to reduce relapse rate following pregnancy [Achiron et al. 1996; Haas
and Hommes, 2007].
Corticosteroids
The use of corticosteroids in MS has primarily
focused on treatment of exacerbations, but there is
evidence to support the use of steroids as a preventative therapy. Data from the Optic Neuritis
Treatment Trial (ONTT) suggest that the use of
high-dose steroids reduces the risk of development
of MS at 2 years following the initial optic neuritis
event [Beck et al.1993]. Further, a randomized,
controlled phase II trial utilizing pulsed highdose methylprednisolone over the course of 5 years
showed a reduction in brain atrophy, T1 lesion
volume and disability progression, but failed to
show a difference in annualized relapse rate or T2
lesion volume [Zivadinov et al. 2001].
Methylprednisolone in combination with IFNβ1a did not show reduction in disability progression compared with IFN-β1a alone [Ravnborg
et al. for The MECOMBIN study, 2010]. A similar study by Sorensen and colleagues showed a
decrease relapse rate when methylprednisolone
was used in combination with IFN-β1a subcutaneously compared with IFN-β1a alone [Sorensen
et al. 2009]. The advent of new immunomodulatory
therapies and concerns for long-term adverse
effects of steroids largely limit their use as a
long-term preventative therapy.
What is in the pipeline?
At this time, six new drugs have entered or completed phase II and III clinical trials, three of which
are oral drugs. These include laquinimod, teriflunomide and dimethyl fumarate, and three mAbs—
alemtuzumab, daclizumab and rituximab.
Laquinimod
Laquinimod is an orally administered immunomodulator being studied in patients with
RRMS and SPMS. The anti-inflammatory properties of laquinimod are thought to be secondary
to downregulation of MHC class II gene transcription factors, stimulation of neurotrophic
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factors, activation of the anti-inflammatory IL-4
pathway in CD4+ T cells, promotion of apoptosis in CD8+ T cells and B cells, and suppression
of the metabolic activity of CD14+ and natural
killer cells [Thöne et al. 2011]. Therefore, it is
proposed that laquinimod acts by affecting the
Th1 to Th2 cytokine shift. Two phase II trials in
patients with RRMS and SPMS have been completed, with varying results [Comi et al. 2008;
Polman et al. 2005]. In the phase III Assessment
of Oral Laquinimod in Preventing Progression
in Multiple Sclerosis (ALLEGRO study), laquinimod significantly improved clinical and radiologic
outcomes, resulting in a 23% reduction in relapse
rate, and a 37% reduction in mean cumulative
number of Gad+ lesions [Comi et al. 2012b].
The Benefit Risk Assessment of Avonex and
Laquinimod (BRAVO) study is another phase III
study comparing laquinimod at 0.6 mg/day with
weekly intramuscular IFN-β1a at 30 μg in patients
with RRMS. At the 5th Joint Triennial Congress
of the European and Americas Committees for
Treatment and Research in Multiple Sclerosis
(ECTRIMS/ACTRIMS), the results of a randomized, placebo-controlled, double-blind, activecomparator phase III study, BRAVO, were
presented. This study did not achieve its primary
endpoint of reducing the ARR. Laquinimod
appears to be well tolerated, with only transient
and dose-dependent increases in liver enzymes
[Vollmer et al. 2011].
Teriflunomide
Teriflunomide is an oral agent that inhibits the
synthesis of DNA pyrimidine bases in rapidly
dividing cells such as T and B cells and macrophages, and may thereby reduce inflammation
(and likely produce immune suppression). It
reversibly inhibits dihydroorotate dehydrogenase, a key enzyme involved in de novo pyrimidine synthesis. Because activated lymphocytes
largely depend on de novo pyrimidine synthesis,
pyrimidine depletion might result in inhibition
of immune-cell proliferation [Korn et al. 2004].
There is some evidence from in vitro studies suggesting that teriflunomide induces Th2-mediated
anti-inflammatory cytokine activation. A phase
II study examined the efficacy of teriflunomide
daily doses of 7 and 14 mg compared with placebo over 36 weeks in patients with RRMS and
SPMS. Teriflunomide efficacy was measured by
the number of new lesions (T2 and Gad+) as
observed on MRI scans. Active treatment resulted
in a 61% reduction in MRI activity compared
http://tan.sagepub.com
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with placebo. Teriflunomide was generally well
tolerated and occurrence of adverse events was
similar between the two treatment groups. Serious
adverse events included elevated liver enzyme
levels, hepatic dysfunction, neutropenia, rhabdomyolysis and trigeminal neuralgia. A 2-year,
double-blind, placebo-controlled phase III study
in RRMS (The Teriflunomide Multiple Sclerosis
Oral [TEMSO] study) was recently published.
The study showed that at 7 and 14 mg the ARR
was approximately 30% compared with placebo.
Teriflunomide significantly reduced disability
progression compared with placebo [O’Connor
et al. 2011].
Dimethyl fumarate
A novel oral therapy under development is dimethylfumaric acid (BG-12), which is related to fumaric acid, an agent used for many years in psoriasis
(principally in Europe). BG-12 is thought to
inhibit immune cells and molecules involved in
MS attacks on the brain and spinal cord. Fumarates
appear to modulate a number of oxidative pathways and thereby may influence the mechanisms
by which autoimmune mechanisms provoke
downstream pathways of tissue damage. In vitro
studies with the ester dimethyl fumarate (DMF)
described an inhibitory effect on nuclear factor κB
dependent transcription of tumor necrosis factor
α induced genes in human endothelial cells
[Moharregh-Khiabani et al. 2009]. Although its
exact MOA is not known, BG-12 is thought to
inhibit immune cells by stimulating the expression
of anti-inflammatory cytokines, such as IL-10,
IL-4 and IL-5. Hence, it is thought that DMF can
induce a shift from a proinflammatory Th1 to an
anti-inflammatory Th2 T-cell response [Wierinckx
et al. 2005]. In addition, BG-12 may have a neuroprotective therapeutic effect by inducing phase II
detoxification genes and upregulation of the phase
II detoxification enzyme, nicotinamide adenine
dinucleotide phosphate oxidase:quinone oxidoreductase-1 [Wierinckx et al. 2005]. In an earlier
phase II study, compared with placebo, the BG-12
dose of 240 mg three times a day led to a 69%
reduction in active inflammation on MRI scans
from weeks 12 to 24 [Kappos et al. 2008]. A phase
III pivotal trial showed that 240 mg of BG-12,
administered twice a day, met the primary study
endpoint, demonstrating a highly statistically
significant reduction in relapses in patients with
RRMS, as well as providing a statistically significant reduction in ARR in the number of new or
newly enlarging T2 hyperintense lesions, in new
http://tan.sagepub.com

Gad+ lesions, and in the rate of disability progression at 2 years as measured by the EDSS [Biogen
Idec, 2011]. Side effects of BG-12 included
abdominal pain, flushing, headache and fatigue
[Schimrigk et al. 2006].
Results of the phase III Efficacy and Safety of
Oral BG00012 in Relapsing-Remitting Multiple
Sclerosis (DEFINE) trial were presented at the
5th Joint Triennial Congress of the European and
Americas Committees for Treatment and Research
in Multiple Sclerosis (ECTRIMS/ACTRIMS). It
showed that BG-12 at 24 mg twice or three times
a day reduced the relapse rate by 49% and 50%,
respectively.
Alemtuzumab
Alemtuzumab is a mAb that binds to CD52, an
epitope common to most cells within the immune
system. Treatment with this agent essentially
results in an antibody-mediated ablation of the
circulating immune system. Alemtuzumab binds
to B and T lymphocytes, resulting in antibodydependent cell lysis, and subsequent elimination
from the bone marrow and blood, with the
effect lasting up to 16 months. This agent appears
to rapidly and profoundly establish both clinical
and radiographic remission of MS; however,
alemtuzumab has been associated with the
risk of developing new autoimmune disorders
(autoimmunity), including thyroiditis, idiopathic
thrombocytopenic purpura and Goodpasture’s
syndrome. Cossburn and colleagues found that
the cumulative risk of autoimmunity in MS following the use of alemtuzumab was 22.2%, most
frequent between 12 and 18 months following
the first dose and evident for up to 5 years
[Cossburn et al. 2011].
Other adverse events associated with alemtuzumab include infections, increased cancer risk,
organ toxicity and infusion-associated hypersensitivity reactions with potentially resultant neutralizing antibodies. Studies of alemtuzumab in
the treatment of patients with RRMS and SPMS
have suggested efficacy in the suppression of
ARR, but with variable results in preventing progression of disability, depending on stages of the
disease [Corboy et al. 2010].
The phase II trial CAMMS223 compared alemtuzumab (12 or 24 mg intravenously on 5 consecutive days during the first month and on
3 consecutive days at months 12 and 24) with
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IFN-β1a, 44 μg subcutaneously three times a
week. Alemtuzumab demonstrated a decrease
in sustained disability (75% at 12 mg dose and
67% at 24 mg dose) and a decrease in relapse
rate (69% at 12 mg and 79% at 24 mg) compared with IFN-β1a subcutaneously [Panitch
et al. 2008].
Comparison of Alemtuzumab and Rebif
Efficacy in Multiple Sclerosis Study 1 (CARE
MS I), a 2 year phase III trial comparing alemtuzumab with subcutaneous IFN-β1a in treatment-naïve patients showed a reduction
in relapse rate by 55% but did not show statistical
significance regarding slowing disease process.
A second phase III trial (CARE MS II) is currently in progress.
Daclizumab
Daclizumab is an engineered human antibody that
blocks the IL-2 receptor on immune cells. IL-2 is a
potent immune stimulator and thus by blocking it,
this therapy putatively dampens immune responses
(including autoimmune responses).
The clinical benefit derived from daclizumab has
been linked to the expansion of immunoregulatory CD56 natural killer cells, and the resulting
downregulation of adaptive T-cell responses
[Bielekova et al. 2006]. A recent open-label phase
II trial using subcutaneous daclizumab at 2 mg/kg
in patients with MS whose condition showed an
inadequate response to IFN-β therapy demonstrated a 72% reduction in the number of new or
enlarged contrast-enhancing lesions at week 24
compared with patients receiving IFN-β alone
[Wynn et al. 2011]. A phase III trial of daclizumab
versus IFN-β1a is ongoing (DECIDE study).
Daclizumab is currently FDA approved for use in
organ transplant patients.
Ocrelizumab
Ocrelizumab, the humanized version of rituximab,
is an antibody that targets CD20, a cell surface
epitope on developing B cells. Upon binding to its
target, these agents provoke rapid destruction of
circulating B cells via two principal mechanisms,
antibody-dependent and complement-dependent
cellular cytotoxicity.
The effect of CD20 targeting has ramifications for
both B- and T-cell immune function, and as such,
these treatments can be associated with risk of
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infection (including PML), and organ toxicity.
Ocrelizumab, a humanized mAb against human
CD20, is currently under investigation in a phase
III program called ORCHESTRA (OPERA I and
II in RRMS and ORATORIO in PPMS) evaluating its efficacy in patients with MS. A phase II trial
comparing ocrelizumb 600 mg and 2000 mg with
placebo showed a significant reduction in brain
lesions (89% and 96%, respectively) and ARR
(80% and 73%, respectively) [Kappos et al. 2011].
Discussion
The pharmacological armamentarium for MS
has significantly expanded in the past 20 years
and many new drugs are on the horizon. Each of
these drugs has their own niche for utilization.
There are significant data about long-term safety
and efficacy of all the IFN-β and GA agents which
should be considered first line in newly diagnosed
patients. For patients whose condition fails to
respond to first-line agents (i.e. recurrent clinical
exacerbations, significant disease burden with
new and enhancing lesions) or with an aggressive
disease course at onset alternatives such as natalizumab or fingolimod are appropriate. MOAs,
adverse events and compliance issues should be
considered when choosing a therapy. Off-label
agents also have a place for patients who are
unable to tolerate FDA-approved therapies. These
agents also offered options for intensification of
therapy, although large clinical trials are needed
to determine ideal dosing. The results of efficacy
and safety profiles of emergent oral and intravenous agents are essential to determine their place
in the treatment of patients with MS. With the
advent of new therapies, the need for biomarkers
that can predict a patient’s response to therapy is
imperative. More studies are needed to develop
therapies for halting neurodegeneration, promoting remyelination and promoting neuronal repair.
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